Mark Lowenthal has taken the role of president and chief executive at BioNeutral Group, an infection control specialist based in Morristown, NJ, US.
Lowenthal was previously a member of the Operation Executive Board of AUA Equity Partners. Prior to this he was president of Revlon Europe, Asia and the Middle East, where he was responsible for planning and implementing a restructuring of the company's business, including shifting from an individual country management approach to an integrated global approach.
Lowenthal has also been president and general manager of Almay and vp of marketing at International Playtex.
Andrew Kielbania, BioNeutral’s former interim ceo, said: ‘Mark has a proven record of building sales and value to companies. At the same time, his appointment will allow me to focus my energies on the science side of our business.’
